Funding for this research was provided by:
National Cancer Institute (R01 CA197936, U24 CA213274, K08 CA-248723, R35 CA263816)
Received: 16 August 2021
Accepted: 4 October 2021
First Online: 16 October 2021
: All study subjects had provided signed informed consent for biospecimen analyses under an institutional review board-approved protocol. All animal experiments were approved by the Memorial Sloan Kettering Cancer Center (MSKCC) Animal Care and Use Committee.
: Not applicable.
: AQV reports honoraria from AstraZeneca. MO reports advisory roles for PharMar, Novartis and Targeted Oncology and reports honoraria from Bristol-Myers Squibb and Merck Sharp & Dohme. CMR has consulted regarding oncology drug development with AbbVie, Amgen, Ascentage, Astra Zeneca, Bicycle, Celgene, Daiichi Sankyo, Genentech/Roche, Ipsen, Jazz, Lilly, Pfizer, PharmaMar, Syros, and Vavotek. CMR serves on the scientific advisory boards of Bridge Medicines, Earli, and Harpoon Therapeutics. AQV and CMR are included on a US patent application entitled, “Methods for predicting and treating chemoresistance in small cell lung cancer patients.”